Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3849891 · 1 trial · 2 indications
A summary of TEAEs and AEs, regardless of causality, will be reported in the Reported Adverse Events module
PD: Mean change from baseline on liver inflammation and fibrosis content measured by MRI
| Arm | Type | Description |
|---|---|---|
| LY3849891 (Part A) | EXPERIMENTAL | Single ascending doses of LY3849891 administered subcutaneously (SC) |
| LY3849891 (Part B) | EXPERIMENTAL | Repeated doses of LY3849891 administered SC |
| Placebo (Part A) | PLACEBO_COMPARATOR | Placebo administered SC |
| Placebo (Part B) | PLACEBO_COMPARATOR | Placebo administered SC |
| Name | Type | Description |
|---|---|---|
| LY3849891 | DRUG | Administered SC |
| Placebo | DRUG | Administered SC |
Inclusion Criteria: * Participants must have a body mass index (BMI) within the range greater than or equal to (≥) 25 and less than (\<) 50 kilogram per square meter (kg/m²) inclusive * Participants must have liver fat content ≥10% in Part A and ≥8% for Part B as determined by MRI-PDFF * Participan...
LY3849891 is an investigational small molecule being developed for Metabolic Dysfunction-Associated Steatohepatitis (MASH), a form of fatty liver disease. It is also being studied in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). The drug is in Phase 1 clinical development and has not been approved by regulatory authorities.
LY3849891 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY. The company is conducting clinical trials to evaluate the safety and tolerability of this investigational drug in patients with metabolic liver diseases.
LY3849891 is in Phase 1 clinical development. A Phase 1 trial has been completed, and the drug remains investigational. It has not been approved by the FDA or any other regulatory agency, and its safety and efficacy have not been established.
LY3849891 has one completed clinical trial, registered as NCT05395481. This was a Phase 1, single-ascending and repeated dose study in participants with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). The trial enrolled 115 participants and was conducted in the United States, Japan, and Puerto Rico.
Yes, LY3849891 is a small molecule therapeutic. It is being developed as an oral treatment for Metabolic Dysfunction-Associated Steatohepatitis (MASH) and related fatty liver conditions. The drug is currently in early-stage clinical testing.